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The critical role of oligodendrocytes in producing andmaintainingmyelin that supports rapid axonal conduction in CNS neurons is well
established.More recently, additional roles for oligodendrocytes have been posited, including provision of trophic factors andmetabolic
support for neurons. To investigate the functional consequences of oligodendrocyte loss, we have generated a transgenicmousemodel of
conditional oligodendrocyte ablation. In this model, oligodendrocytes are rendered selectively sensitive to exogenously administered
diphtheria toxin (DT) by targeted expression of the diphtheria toxin receptor in oligodendrocytes. Administration of DT resulted in
severe clinical dysfunction with an ascending spastic paralysis ultimately resulting in fatal respiratory impairment within 22 d of DT
challenge. Pathologically, at this time point,mice exhibited a loss of26%of oligodendrocyte cell bodies throughout the CNS. Oligoden-
drocyte cell-body loss was associated with moderate microglial activation, but no widespread myelin degradation. These changes were
accompanied with acute axonal injury as characterized by structural and biochemical alterations at nodes of Ranvier and reduced
somatosensory-evokedpotentials. In summary,wehave shown that adeath signal initiatedwithinoligodendrocytes results in subcellular
changes and loss of key symbiotic interactions between the oligodendrocyte and the axons it ensheaths. This produces profound func-
tional consequences that occur before the removal of the myelin membrane, i.e., in the absence of demyelination. These findings have
clear implications for the understanding of the pathogenesis of diseases of the CNS such as multiple sclerosis in which the oligodendro-
cyte is potentially targeted.
Introduction
The oligodendrocyte is a specialized glial cell within the CNS that
is responsible for producing the myelin that ensheaths axons and
forms the nodes of Ranvier that permit saltatory nerve conduc-
tion. Dysfunction and death of oligodendrocytes has been de-
scribed in various demyelinating pathologies including the
leukodystrophies and multiple sclerosis (MS) (Lucchinetti et
al., 1996; Dowling et al., 1999; Feigenbaum et al., 2000).
Autoimmune-induced inflammatory demyelination has tradi-
tionally been the assumed pathogenic mechanism in MS
(Weiner, 2004; Frohman et al., 2006). However, recent detailed
examinations of pathological specimens have challenged this
view. On the one hand, significant axonal degeneration occurs
early in disease (Trapp et al., 1998; 1999; Kuhlmann et al., 2002),
even in the absence of demyelination (Nikic´ et al., 2011), raising
the possibility of axonal attack by activated microglia and/or
macrophages. On the other hand, oligodendrocyte death in acute
MS can occur without significant immune cell infiltration andmay
precede the development of inflammatory demyelinated plaques
(Barnett and Prineas, 2004; Marik et al., 2007; Henderson et al.,
2009). Moreover, periplaque tissue in evolving MS lesions exhibits
oxidative damage that is often localized within apoptotic oligoden-
drocytes (Haider et al., 2011). Thus, oligodendrocytopathy could
represent the primary event in newly formingMS lesions.
Experimental models of primary oligodendrocytopathy could
assist in unraveling the complex pathological sequelae in MS. To
this end, specific oligodendrocyte-targetingmodels have recently
been developed using diphtheria toxin (DT) as the driver of
oligodendrocyte death (Buch et al., 2005; Traka et al., 2010;
Pohl et al., 2011). These binary genetic approaches involve
oligodendrocyte-restricted Cre or CreER-regulated expression
of the simianDT receptor (DTR) or the A subunit of DT (DT-A).
In the former scenario, expression of DTR in oligodendrocytes
renders naturally DT-resistant mouse cells susceptible to intra-
peritoneally injected DT. Once internalized, DT catalyzes ADP-
ribosylation of eukaryotic elongation factor 2, which results in
inhibition of protein translation and ultimately, apoptosis
(Collier, 2001). Induction of oligodendrocyte apoptosis in these
mice causes demyelination, myelin splitting, and/or vacuoliza-
tion resulting in motor pathologies of variable severity (Buch et
al., 2005; Traka et al., 2010; Pohl et al., 2011).
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We have generated a novel transgenic mouse denoted MBP-
DTR (Line 100A) for targeted ablation of oligodendrocytes that
does not rely upon Cre/loxP transgenics. In these mice, expres-
sion of human DTR is regulated by the proximal 1.96 kb pro-
moter of mouse myelin basic protein (MBP) gene which directs
specific expression tomature oligodendrocytes (Gow et al., 1992;
Shults et al., 2005; Emery et al., 2006). Administration of DT to
MBP-DTR mice leads to loss of oligodendrocyte cell bodies and
the development of severe clinical pathology characterized by
spastic paralysis of the hindlimbs, tremor, ataxia, and kyphosis
that correlates with impairment of electrophysiological proper-
ties of neurones and ultrastructural alterations at the nodes of
Ranvier. Importantly, these changes occurred in the absence of
inflammatory demyelination and demonstrate that axonal pa-
thology occurring in the absence of demyelination can still be
secondary to primary pathology of the oligodendrocyte.
Materials andMethods
Generation of MBP-DTR transgenic mice. The MBP-DTR construct was
generated by excising a LacZ transgene from the pMG2 vector (kindly
provided by Associate Professor Alexander Gow, Wayne State Univer-
sity, Detroit, Michigan; Gow et al., 1992) and replacing it with the coding
sequence (CDS) for human heparin-binding epidermal growth factor
(HB-EGF), a high-affinity DTR. The HB-EGF/DTR CDS was amplified
by high-fidelity PCR from the pRC/CMV/hHB-EGF plasmid (kindly
provided by Professor Eisuke Mekada, Osaka University, Japan). The
resultant MBP-DTR construct was validated by DNA sequencing to
comprise the 1.94 kb proximal promoter of the mouse myelin basic
protein promoter (MBP, corresponding to bases1907 to36 relative
to ATG), the 627 bp human HB-EGF/DTR CDS, and 1.43 kb 3 splicing
and the polyadenylation sequence derived from the human -globin
gene (exon 2, intron 2, exon 3). MBP-DTR plasmid DNA isolated from
maxiprep culture (Qiagen) was further purified by CsCl gradient centrif-
ugation. The DNA was digested with ScaI and SphI producing a 1.7 kb
fragment comprising the plasmid backbone and a 4.7 kb fragment com-
prising the proximalMBP promoter, human HB-EGF (DTR) CDS, and
human -globin polyadenylation sequence. The DNA fragments were
separated on a 1.5% agarose (Lonza SeaPlaque; Fisher Scientific)/TBE gel
and the 4.7 kb ScaI/SphI MBP-DTR fragment was extracted from the
corresponding gel slice by-Agarase I digestion (NewEngland BioLabs).
The extracted DNA was dialyzed (“v” series membrane, 0.05 m pore
size; Millipore) with microinjection buffer and diluted to 2g/ml before
microinjecting into themale pronuclei of fertilizedC57BL/6 oocytes. Tail
biopsies from the offspring of oocyte recipients were assessed for incor-
poration of the transgene by Southern blot and PCR analysis. For South-
ern blot analysis, genomic DNA was digested with BstXI followed by
agarose gel electrophoresis. Gel blots prepared using nitrocellulosemem-
branes (HybondN; GEHealthcare) were hybridizedwith a 32P-labeled
DNA probe generated by PCR amplification of a 629 bp product from
the MBP-DTR construct that encompassed part of the murine MBP
promoter and humanDTR sequence (sense primer: 5-CAGGCCCACATT
CATATC-3; antisense primer: 5-TCTTCCCTAGCCCCTTGCCTTTCT-
3). PCR genotyping of tail biopsy DNA was performed using primers
targeting a 512 bp amplicon encompassing part of the vector between the
promoter andHB-EGFCDSandpart of thehumanHB-EGFCDSwith80%
homology to murine HB-EGF (sense primer: 5-GCTCGAATAATTCTAG
GGTC-3; antisense primer: 5-GGTCATAGGTATATAAGCGA-3). Of
the 18 founders that exhibited germline transmission of the MBP-DTR
transgene, we describe the characterization of one line denotedMBP-DTR
Line 100Awhich is hereafter referred to asMBP-DTRmice.
Animal cohorts. All experimental mice were maintained on a pure
C57BL/6 backgroundon a 12 h light-dark cycle and providedwith rodent
chow (Barastoc Products) and water ad libitum. Experimental cohorts
were generated by crossing MBP-DTR heterozygotes with wild-type
C57BL/6 to produce heterozygous MBP-DTR and wild-type litter-
mates or, alternatively, by crossing MBP-DTR heterozygotes with
Pdgfra-CreERT2/:R26R-YFP/ mice to generate Pdgfra-CreERT2/:
R26R-YFP/:MBP-DTR/ and Pdgfra-CreERT2/:R26R-YFP /:
wild-type littermates. Pdgfra-CreERT2 mice (Rivers et al., 2008) and R26R-
YFPmice (Srinivas et al., 2001) were kindly provided by Professor William
D. Richardson (Wolfson Institute for Biomedical Research, University Col-
legeofLondon)andProfessorFrankCostantini (ColumbiaUniversityMed-
ical Center, New York), respectively. Experimental procedures were
conducted inaccordancewithNationalHealthandMedicalResearchCoun-
cil guidelines and were approved by the animal ethics committees of the
Florey Neuroscience Institutes and University of Queensland.
Intraperitoneal injection and gavaging. For the initial experimental co-
horts, mice aged 8–10 weeks were given a single intraperitoneal injection
of 200 ng DT (2 g/ml in saline; Sigma) or an equal volume (100 l) of
saline as control. For subsequent cohorts, DT was administered as a
single intraperitoneal injection at a fixed dose of 10 g/kg (prepared at 1
g/ml in saline); vehicle controls received saline at a dose of 10 l/g.
Three experimental groups were typically assessed:MBP-DTRmice ad-
ministered DT, MBP-DTR mice administered saline, and wild-type lit-
termates administeredDT. To induce recombination in Pdgfra-CreERT2:
R26R-YFP:MBP-DTR and Pdgfra-CreERT2:R26R-YFP:wild-type mice,
tamoxifen (prepared at 40 mg/ml in 50°C corn oil; Sigma) was adminis-
tered by oral gavage (300 mg/kg/d) for 4 consecutive days, commencing
7 d before DT challenge. Following DT or saline challenge, mice were
weighed and monitored daily for signs of neurological impairment. The
clinical course was scored as follows: 0 healthy, 1 pelvis lowered, 2
pelvis on ground, 3 hindpaw slippage, 4 kyphosis, 5 tail spasticity,
6 upper torso lowered, and 7 labored breathing.
Immunohistochemistry.Mice were deeply anesthetized with 100mg/kg
sodium pentobarbitone then transcardially perfused with PBS followed
by 4% paraformaldehyde (PFA)/PBS. Extracted brains, spinal cords, and
sciatic nerves were postfixed in 4% PFA/PBS for 2 h on ice, rinsed briefly
in PBS, and then equilibrated in 20% sucrose/PBS for 24 h before em-
bedding in Tissue-Tek O.C.T. compound (Sakura FineTek) and freezing
on an isopentane bath over dry ice. Tissue was stored at 80°C until
sectioned. Ten-micron-thick cryosections of the brain (coronal), spinal
cord (coronal and longitudinal), and sciatic nerve (longitudinal) were
collected onto Superfrost Plus slides (Menzel Gla¨ser) and air-dried for
1 h before storing at80°C until stained.
Cryosections were blocked for 1 h with PBS containing 0.3% Triton
X-100 and 10% normal serum (goat or donkey depending upon host of
secondary antibodies). In some instances serum was replaced with 1%
BSA and 0.1% gelatin. Primary antibodies diluted in 10%normal serum/
PBS were applied for 16 h at 4°C or at room temperature. Slides were
rinsed three times in PBS (5 min each) before application of secondary
antibodies for 30 min at room temperature. Slides were rinsed again,
counterstained with Hoechst 33342 (1 g/ml; Invitrogen), and cover-
slipped with Mowiol mounting medium. For DTR immunohistochem-
istry, an Alexa Fluor 488-conjugated goat anti-FITC antibody (1:200;
Invitrogen) was used as a tertiary antibody after the secondary antibody
rinse to amplify the DTR signal.
The following primary antibodies were used: rabbit anti-pan-
neurofascin (1:2000; a generous gift from Professor Peter Brophy, Uni-
versity of Edinburgh), mouse anti-APC/CC-1 (1:100; Calbiochem),
mouse anti-ankyrin G (1:200; Santa Cruz Biotechnology), mouse anti-
oligodendrocytes (1:5000, clone NS-1/RIP; Millipore), rabbit anti--
amyloid precursor protein (1:300; Zymed), rat anti-PDGFR (1:500,
clone APA5; BD PharMingen), rabbit anti-NG2 (1:200; Millipore), rab-
bit anti-cleaved caspase-3 (1:200; Cell Signaling Technology), rabbit
anti-CD3 (1:200; Dako), rabbit anti-Krox20 (1:200; Covance), rat anti-
CD11b (1:200; BD PharMingen), mouse anti-glial fibrillary acidic pro-
tein (GFAP) (1:200, clone GA5; Millipore), rabbit anti-GFAP (1:500;
Dako), goat anti-HB-EGF (1:200; R&D Systems), rabbit anti-Iba1 (1:
1000; Wako Industries), mouse anti-myelin-associated glycoprotein
(MAG) (1:1000; Millipore), rabbit anti-MBP (1:200; Millipore Biosci-
ence Research Reagents), mouse anti-NeuN (1:100;Millipore Bioscience
Research Reagents), mouse anti-S100 (1:1000, clone SH-B1; Sigma),
rabbit anti-Olig2 (1:200; Millipore), mouse anti-Kv1.2 (1:500; Neuro-
Mab), rabbit anti-Nav1.6 (1:100; Alomone Labs), and mouse anti-
SMI312 (1:1000; Covance). Secondary antibodies raised in goat or
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donkey and conjugated to FITC, TRITC, or NL557 were purchased from
Jackson ImmunoResearch or R&D Systems and used at 1:200 dilution.
Slides were examined using an AxioPlan2 fluorescent microscope
(Zeiss), and images were captured using an AxiocamHRc camera (Zeiss)
using Axiovision 7.2 software. For comparative analysis of the intensity
of myelin protein labeling, photomicrographs were converted to gray-
scale and analyzed using ImageJ software (National Institutes of Health;
NIH). Intensity was defined as the average gray value obtained from all
pixels within the region of interest above background. Confocal analysis
of nodal protein expression was performed using a FluoView FV1000
confocal microscope (Olympus) under a 40 oil objective using Flu-
oView confocal software (Olympus).
TUNEL. For combined immunohistochemistry and TUNEL, 10-m-
thick coronal cryosections of fresh frozen brain tissuewere collected onto
Superfrost Plus slides, air-dried for 5 min, postfixed in 4% PFA/PBS for
20 min at room temperature, and rinsed three times in PBS. Immuno-
histochemistry was conducted as previously described using TRITC-
conjugated secondary antibodies then processed for TUNEL using the
Fluorescein In Situ Cell Death Detection Kit (Roche) according to the
manufacturer’s protocol. Slides were counterstainedwithHoechst 33342
and coverslipped as described previously. To quantify the extent of apo-
ptosis, the number of TUNELHoechst cells in the cerebral cortex and
corpus callosum were counted (bregma level 0.5 mm) in MBP-DTR
andwild-typemice (n 4 per genotype) at both 5 and 15 d followingDT
challenge and expressed as TUNEL cells per millimeter squared. For
statistical analysis, the data were analyzed by one-way ANOVA followed
by Bonferroni’s post hoc tests.
Electron microscopy. Following perfusion/fixation, the lumbar spinal
cord and sciatic nerves were postfixed in Karnovsky’s buffer (2.5% glu-
taraldehyde, 4% PFA, 0.1 M sodium cacodylate, pH 7.3) for 16 h at 4°C,
rinsed three times in PBS, and stored in 0.1 M sodium cacodylate, pH 7.3,
at 4°C for 24 h. The tissue was postfixed in a solution of 2% w/v osmium
tetraoxide and 1.5% w/v potassium ferricyanide and embedded in
Spurr’s resin. The dorsal funiculus of the lumbar spinal cord and sciatic
nerves were sectioned at 0.5 m thickness on an ultramicrotome (Ul-
tracut S; Reichert) in transverse orientation for analysis of g-ratios (dor-
sal funiculus, sciatic nerve) or longitudinally (dorsal funiculus) for
assessment of nodes of Ranvier.
Semithin (0.5 m) transverse sections were stained with methylene
blue and imaged at 10,000 magnification. Fibers within a 121.5 m2
region of interest (ROI) within each dorsal funiculus (two ROI assessed
per animal, n  2 animals per group) or a 3.07 mm2 ROI within each
sciatic nerve (four ROI assessed per animal, n  2 animals per group)
were assessed using ImageJ software (NIH). For each axon, the axonal
area excluding the myelin sheath and the entire fiber area including the
myelin sheath were independently outlined and the area calculated using
the “measurement” function within ImageJ. In addition, as a measure of
myelin integrity, the axonal and fiber diameters were measured and used
to calculate g-ratios (ratio of axonal diameter to fiber diameter) (Sher-
man and Brophy, 2005). Results were analyzed using multivariate
ANOVA followed by Tukey’s post hoc analysis using SPSS 15.0.
For nodal analysis, the ROI in the dorsal funiculus was confirmed by
methylene blue staining before collection of ultrathin (90 nm) sections.
Ultrathin sections were postfixed in lead nitrate and urinyl acetate,
mounted on copper grids, and examined in anElmskop 102 transmission
electron microscope (Siemens). Photomicrographs were captured at
25,000 magnification and negatives were scanned to generate high-
resolution computer images for analysis. Nodes of Ranvier were exam-
ined qualitatively for indications of ultrastructural abnormalities. The
percentage of nodes within the dorsal funiculi of DT-challenged MBP-
DTR (n  2) and wild-type (n  2) mice exhibiting paranodal loop
eversion was determined on the basis of assessments by two expert my-
elin biologists who were blinded to the identity of each group.
Somatosensory-evoked potentials. Six DT-challenged MBP-DTR mice
at clinical end point and five matching DT-challenged wild-type litter-
mates were anesthetized with an intraperitoneal injection of ketamine
(0.1 mg/kg) and xylazine (0.01 mg/kg). Depth of anesthesia was checked
by the loss of response to rear paw pinch and additional injection of the
anesthetic solution was provided as required. The body temperature of
animals was maintained at 36.5°C using a controlled heating pad. Ani-
mals were mounted in a stereotaxic frame (model 962; Kopf Instru-
ments) and the scalp incised longitudinally and retracted to expose the
skull. A hole was drilled above the somatosensory cortex (anteroposte-
rior,0.5; lateral, 2.5; and dorsal, 1 mm) to allow insertion of a borosili-
cate glass recording electrode filled with 3 M saline. A second hole was
drilled on the opposite side above the contralateral frontal lobe to allow
for the insertion of the reference electrode between the skull and the
meninges. Stimulating electrodes made of stainless steel (25 g) were in-
serted at the sciatic notch and connected to a constant current generator
(A385; World Precision Instrument). Local field potentials were re-
corded at 5 kHz and bandpass filtered (30 Hz–1.8 kHz). Each animal
received 50 sciatic notch stimulations (5 mA; 0.2 ms; interspike interval,
15 s); the onset of the field potential immediately following the stimula-
tion artifact was used to measure the nerve conduction velocity (values
are mean SEM).
Measurement of compound action potentials in isolated sciatic nerve.
Eight DT-challenged MBP-DTR mice at clinical end point and three
matching DT-challenged wild-type littermates were overdosed with so-
dium pentobarbitone (100 mg/kg). Sciatic nerves were isolated and
placed in saline at room temperature. Nerves were coated in liquid par-
affin oil, and the proximal and distal ends were placed onto gold-plated
fixed electrodes (proximal end, stimulating electrode; distal end, record-
ing electrode 10 mm from proximal electrode; medial position, ground-
ing electrode) in a humidified 37°C chamber. Square-wave stimulating
pulses of 100 s duration were delivered at 30 s intervals using a
constant-voltage stimulus isolator (PowerLab 4/20; ADInstruments) at
progressive intensities from 0.2 mV up to 10 V. Monophasic compound
action potentials (CAPs) generated at suprathreshold stimulus intensity
(6 V) were amplified using a differential bioamplifier (Bio Amp;Maclab)
and digitized using Scope software (v4.1; ADInstruments). Post hoc anal-
ysis was performed using LabChart Reader for Mac (ADInstruments).
Results
MBP-DTRmice express DTR exclusively in oligodendrocytes
in the CNS
To assess the consequences of oligodendrocyte ablation in the
adult CNS, we generated transgenicmice that express DTRunder
the regulatory control of the proximal promoter for the MBP
gene (see Materials and Methods; Fig. 1A). We used a 1.94 kb
MBP promoter that had previously been shown to direct trans-
gene expression specifically to the mature oligodendrocyte lin-
eage (Gow et al., 1992; Wrabetz et al., 1998; Emery et al., 2006).
Eighteen germline-transmitting MBP-DTR transgenic founders
were identified by Southern blot (Fig. 1B) and PCR analysis (Fig.
1C; seeMaterials andMethods).We performed a series of immu-
nohistochemical analyses to assess the expression pattern of DTR
in the adult CNS ofMBP-DTR and wild-type littermates. Immu-
nolabeling was conducted using an antibody that specifically de-
tects human HB-EGF/DTR, but not its murine homolog. Of the
MBP-DTR lines identified, five lines expressed DTR in 100% of
the oligodendrocytes. Here we characterize the phenotype of one
of these five transgenic lines denoted MBP-DTR Line 100A. As-
sessment of coronal sections of the adult forebrain inMBP-DTR
Line 100Amice, referred to hereafter asMBP-DTR, revealed that
DTR was highly expressed in white matter tracts (Fig. 1D),
whereas only low-level, nonspecific labeling was observed in
wild-type littermates (Fig. 1E). We confirmed that DTR was
expressed in mature oligodendrocytes in MBP-DTR mice by
multilabel immunohistochemistry. Specifically, all CC-1 oligo-
dendrocytes identified in sections from MBP-DTR mice were
found to coexpress DTR (Fig. 1F), whereas no DTRwas detected
in any CC-1 oligodendrocytes in wild-type littermates (Fig.
1G). DTR expression in transgenic mice was found not only
within the cell bodies of CC-1 oligodendrocytes but also within
the processes of oligodendrocytes identified by colocalization of
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DTR and MBP (Fig. 1H–J) as well as
of DTR andRIP (Fig. 1K–M). In contrast,
DTR was not expressed by any other neu-
ral cell population examined including
NeuN neurons (Fig. 1N), PDGFR oli-
godendrocyte progenitors cells (Fig. 1O),
Iba1microglia (Fig. 1P), orGFAPastro-
cytes (data not shown). Together, these
experiments demonstrate the successful
generation of MBP-DTR transgenic mice
that expressDTRexclusivelywithin thema-
ture oligodendrocyte population of the
CNS, in a pattern that closely reflects the ex-
pression of myelin proteins.
Severe clinical andmotor deficits in
MBP-DTRmice following DT challenge
To ablate oligodendrocytes, we adminis-
tered a single 200 ng dose of DT to MBP-
DTR transgenicmice (n 9) andwild-type
littermates (n  8), or an equivalent vol-
ume of saline toMBP-DTRmice (n 6).
The two control groups, wild-type mice
administeredDT andMBP-DTRmice ad-
ministered saline, did not shown any clin-
ical changes over the subsequent 3 weeks.
In contrast,MBP-DTRmice injected with
DT exhibited progressive motor deficits
that typically began at 9 d after DT admin-
istration and became profound in the next
5–6 d. The maximum survival time fol-
lowing the onset of clinical impairment
was 8 d. DT-challenged transgenic ani-
mals exhibited hindlimb clasping when
held by the tail, an ataxic gait, hindlimb
paralysis, tail spasticity, and thoracic ky-
phosis (Fig. 2A). The phenotype rapidly
progressed to include forelimb weakness,
respiratory impairment (labored breath-
ing), reduced mobility, lethargy, and
weight loss, at which time disabled ani-
mals and their matching controls were
killed, a time point we have termed the
clinical end point. A plot of survival time
to clinical end point following DT chal-
lenge demonstrates that all MBP-DTR
Figure 1. Generation ofMBP-DTR transgenic mice expressing DTR within the mature oligodendrocyte population of the adult
CNS. A, Schematic representation of the ScaI/SphI-linearized MBP-DTR construct used to generate MBP-DTR founders. The con-
struct comprises the 1.94 kb proximal promoter of themousemyelin basic protein promoter, the 627 bp human HB-EGF/DTR CDS,
and the 1.43 kb 3 splicing and the polyadenylation sequence derived from the human -globin gene. Arrowheads depict the
sense and antisense primers used for PCR genotyping. The solid black line indicates the size and position of the 32P-labeled probe
used for Southern blot analysis of BstXI-digestedmouse tail DNA.B, Southern blot analysis of BstXI-digested genomicDNA isolated
frommouse tail biopsies used to identifyMBP-DTR (tg) founders; note the absence of signal at 1.7 kb in thewild-type (wt) sample.
Hybridization was performed using a 629 bp 32P-labeled DNA probe that identified a 1.7 kb BstXI fragment generated from the
MBP-DTR sequence. C, PCR genotyping using primers that amplify a 512 bp product from the MBP-DTR transgene enabled
discrimination of MBP-DTR (tg) from wild-type (wt) mice. D, E, Immunohistochemical assessment of DTR expression in the
forebrain using an anti-human HB-EGF antibody revealed DTR expression within white matter tracts ofMBP-DTR (D) but not
4
wild-type (E) mice. F,G, Immunohistochemical assessment of
DTR (green) expression among CC-1 (red) immunoreactive oli-
godendrocytes in the corpus callosum of MBP-DTR (F) versus
wild-type (G) mice. Nuclei were stained with Hoechst 33258
(blue). H–J, DTR expression (H, green) in the corpus callosum
colocalizedwithMBP (I, red), as revealed in themerged image
(J). K–M, DTR expression (K, green) was localized to both the
cell body and processes of RIP-labeled oligodendrocytes (L,
red), as shown in themerged image (M). Nuclei were counter-
stained with Hoechst. N–P, DTR expression (green) was not
observed in NeuN-labeled (red) neuronal cell bodies (N), in
PDGFR-labeled (red) oligodendrocyte progenitor cells (O) or
in Iba1-labeled (red) microglia (P, confocal stack). CC, corpus
callosum, Ctx, neocortex; Str, striatum; z, z-axis projection.
Scale bars: F, G, K–P, 50m; (in J) H–J, 200m.
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Figure 2. DT-challengedMBP-DTRmice exhibit progressive motor deficits and oligodendrocyte loss. A,MBP-DTRmice challenged with DT developed progressive clinical symptoms from day 9
postchallenge onward (seeMaterials andMethods for description of clinical scores). Data points represent the average score for all animals (n 9MBP-DTRmice, DT-injected; n 6MBP-DTRmice,
saline-injected; n 8WTmice, DT-injected) on each day. The apparent decrease in average disease severity at day 17 reflects the need to kill themost severely affected animals (n 2) on day 16
(B), leaving animalswithmoremoderate disease severity to influence average clinical score. No clinical changeswere observed inwild-type controls injectedwithDT or inMBP-DTR controls injected
with saline.B, Plot of survival time to clinical end point after DT challenge inMBP-DTRmice. The clinical end point is defined as the time point at which animals were killed due to the severity of the
clinical phenotype. C, Latency of sciatic notch-evoked local field potentials measured in the somatosensory cortex was increased by 58.5 16% in symptomatic DT-challenged MBP-DTR mice
comparedwith DT-challengedwild-typemice ( p 0.05, Student’s t test).D, Amplitude of sciatic notch-evoked local field potentialsmeasured in the somatosensory cortexwas reduced by 11.5
2.39% in symptomatic DT-challengedMBP-DTRmice comparedwith DT-challengedwild-typemice ( p 0.0016, Student’s t test). E, Density of TUNEL cells inMBP-DTR versuswild-type controls
assessed 5 and 15 d after DT challenge (n 4 per genotype per time point). Two-way ANOVA revealed an overall effect of genotype ( p 0.0001), time ( p 0.005), and an interaction between
these 2 factors ( p0.0003). Bonferroni’spost hoc:MBP-DTRDT (day 15) versuswild-typeDT (day 15),p0.0001.F–N, Combined labeling for TUNEL and cell type-specific antigens revealed
that a subset of TUNEL cells (F, I, L, green) in DT-challengedMBP-DTRmice expressed the oligodendroglial lineagemarker Olig2 (G, red) or themicroglial/macrophage (Figure legend continues.)
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micewere killed between 12 and 22 d afterDT injection (Fig. 2B),
with a median survival time of 16 d.
Disabled mice exhibit electrophysiological abnormalities
To directly assess whether symptomaticMBP-DTRmice chal-
lenged with DT exhibited electrophysiological abnormalities,
we performed in vivo recordings of somatosensory-evoked po-
tentials (SSEPs) by stimulating at the sciatic notch and record-
ing the response in the somatosensory cortex of both MBP-
DTR (n  6) and wild-type animals (n  5) challenged with
DT. In control animals the onset of the local field potential was
detected 8.11  0.29 ms after sciatic notch stimulation,
whereas in symptomatic MBP-DTR animals SSEPs were re-
corded 13.42  0.30 ms after stimulation, representing a
39.6% increase in latency (Fig. 2C). Statistical analysis dem-
onstrated that transmission of the SSEP was significantly faster
in control versus symptomatic MBP-DTR animals (unpaired
Student’s t test; p  0.037). We also observed a statistically
significant reduction in the peak amplitude of SSEPs in symp-
tomatic DT-challengedMBP-DTR animals (31.98 0.86 mV)
compared with control animals (36.13 0.97 mV, p 0.0016,
unpaired Student’s t test) (Fig. 2D).
Induction of oligodendrocyte apoptosis inMBP-DTRmice
following DT challenge
Administration of DT would be expected to result in widespread
oligodendrocyte loss throughout the CNS of MBP-DTR trans-
genic mice. To confirm this, apoptosis within the brains ofMBP-
DTR mice was assessed 5 and 15 d after administration of DT,
corresponding to time points before and during overt clinical
disease, respectively (n  4 per time point). Wild-type animals
administered DT and assessed 5 and 15 d postinjection served as
controls (n  4 per time point). At day 15, the number of
TUNEL cells in the neocortex ofMBP-DTRmice was increased
17.5 relative to wild-type controls (Fig. 2E). Two-wayANOVAof
TUNEL cell density identified a significant effect of both geno-
type (p  0.0001) and time (p  0.0005) and also a significant
interaction (p 0.0003) between these two variables. Bonferro-
ni’s post hoc analysis confirmed that the increase in apoptotic cell
density inMBP-DTRmice compared with wild-type mice at 15 d
post-DT was highly significant (p 0.0001).
We next assessed the phenotype of TUNEL cells and identi-
fied two distinct cell types by combined TUNEL and immuno-
histochemical analysis. Some TUNEL nuclei coexpressed the
transcription factor Olig2 (Fig. 2F–H) suggesting that oligoden-
drocytes were undergoing apoptosis following DT challenge. In
addition, some TUNEL cells expressed CD11b (Fig. 2 I–K) or
Iba1 (data not shown), consistent with a microglial/macrophage
identity. Notably, we never observed colocalization of TUNEL
with NeuN neuronal nuclei (Fig. 2L–N ), and TUNEL was
not identified in GFAP astrocytes or NG2 oligodendrocyte
progenitor cells (data not shown). Since DTR expression in
MBP-DTR mice is restricted to the mature oligodendrocyte
population, the presence of TUNEL microglia likely reflects
an indirect response to the induction of DT-mediated oligo-
dendrocyte apoptosis.
Numbers of CC-1-positive oligodendrocytic cell bodies are
reduced in DT-challengedMBP-DTRmice
To assess the extent of oligodendrocyte ablation following DT
challenge inMBP-DTRmice, we quantified the density of CC-1
oligodendrocytes in the forebrain, cerebellum, and spinal cord at
5 d post-DT injection, and in the forebrain, cerebellum, spinal
cord, midbrain, hindbrain, and brainstem at the clinical end
point. MBP-DTR mice injected with saline and wild-type mice
injected with DT were assessed at the same time points. Repre-
sentative photomicrographs of CC-1 staining in the dorsal funic-
ulus at the clinical end point are shown (Fig. 2O,P). At the day 5
time point, the number of oligodendrocytes per millimeter
squared was not different in any region of the CNS of DT-
challenged MBP-DTR mice when compared with controls (Fig.
2R; multivariate ANOVA, p 0.915). On the other hand, there
was a significant reduction in the total number of CC-1 oligo-
dendrocytes in the CNS of the DT-challengedMBP-DTRmice at
the clinical end point, with an average reduction in cell density of
26 1.6% (multivariate ANOVA, p 0.030). A region-specific
analysis indicated that the numbers of CC-1-positive somata
were significantly reduced in the neocortex (Tukey-HSD, p 
0.006), striatum (p 0.001), cerebellarwhitematter (p 0.001),
spinal cord white matter (p  0.001), spinal cord gray matter
(p 0.001), and hindbrain (p 0.05), but were not significantly
reduced in the corpus callosum (p  0.102), midbrain (p 
0.396), and brainstem (p  0.373; Fig. 2S). Interestingly, in the
dorsal funiculus of the spinal cord white matter which contains
the corticospinal tract there was a 39.5  5.2% loss of CC-1-
positive oligodendrocytes in comparison with DT-challenged
wild-type mice (p 0.05; Fig. 2S).
To assess whether newly differentiated oligodendrocyte
precursor cells (OPCs) contribute to the pool of mature oligoden-
drocytes at clinical endpoint, we usedPdgfra-CreERT2:R26R-YFP:
MBP-DTR transgenic mice and Pdgfra-CreERT2:R26R-YFP:wild-
type littermates to map the fate of OPCs, which all express the
PDGFR receptor, following DT-challenge. Under these condi-
tions we have shown that 52.8% of all PDGFR cells express
YFP within 7 d from the first tamoxifen gavage. We found no
difference in the density of YFP cells that were immunoreactive
for the oligodendrocyte precursor cell marker, PDGFR (p 
0.910; Fig. 2Q), or mature oligodendrocyte marker, CC-1 (p 
0.124; Fig. 2Q), in the lumbar spinal cord of Pdgfra-CreERT2:
R26R-YFP:MBP-DTR (n  4) or Pdgfra-CreERT2:R26R-YFP:
wild-type (n 3)mice. These findings indicate thatOPCs present
at the time of oligodendrocyte ablation do not appreciably differ-
entiate into mature oligodendrocytes in compensation for the
mature oligodendrocytes that are lost following DT challenge in
theMBP-DTRmice.
4
(Figure legend continued.) marker CD11b (J, red) but not the neuronalmarker NeuN (M, red).
Merged images with Hoechst 33342 nuclear counterstain (blue) reveal a TUNEL Olig2 cell
(H) in the cerebral cortex, a TUNEL CD11b cell in the corpus callosum (K), and a TUNEL
NeuN cell in the cortex (N) of anMBP-DTRmouse assessed 15 d post-DT.O,P, Representative
photomicrographs of immunolabeling against the oligodendrocyte marker CC-1 (green) in the
dorsal column (white outline) of wild-type DT (O) andMBP-DTR DT (P) mice. The dorsal
funiculus is outlined in yellow. Nuclei were counterstained with Hoechst 33342 (blue). Q, Den-
sity of YFP cells that are immunoreactive for the oligodendrocyte precursor cell marker
(PDGFR) ormature oligodendrocytemarker (CC-1) in thewhite and graymatter of the lumbar
spinal cord of DT-challenged Pdgfra-CreERT2:R26R-YFP:MBP-DTR (n  4) or DT-challenged
Pdgfra-CreERT2:R26R-YFP:wild-type (n 3) mice. R, S, Density of CC-1 oligodendrocyte so-
mata at day 5 (R) and at clinical end point (S) in DT-challengedMBP-DTRmice compared with
controls. Nd, not determined. Error bars indicate mean SE of the mean. Cb, cerebellum; CC,
corpus callosum; Ctx, cerebral cortex; Str, striatum; SpW, spinal cord white matter; SpG, spinal
cord graymatter;Mb,midbrain; Hb, hindbrain; Bs, brainstem; Df, dorsal funiculus of spinal cord
white matter. Scale bars: (in N) F–N, 20m; (in P) O, P, 100m.
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Reactive changes in microglia/macrophages and astrocytes in
disabledMBP-DTR mice
Wenext assessedwhether oligodendrocyte loss induced an innate
immune response by examining Iba1 immunoreactivity at the
clinical end point in DT-challenged MBP-DTR mice and
matched controls (Fig. 3A–C). Morphological changes in the
Iba1-positive microglial cell population were seen inMBP-DTR;
DT-challengedmice that were not present in control mice. These
changeswere characterized by shortened thickened processes and
increased Iba1 immunoreactivity; however, we did not observe
any microglia with the amoeboid morphology typically associ-
ated with phagocytic activity (Stence et al., 2001). We also found
that the average density of Iba cells throughout the CNS of
DT-challenged MBP-DTR mice relative to DT-challenged wild-
type mice was increased by 39  7% (Fig. 3D; multivariate
ANOVA, p 0.015). Examination of specific regions of interest
revealed that the density of Iba1 cells was significantly increased
in the neocortex (150% of control; p  0.001), striatum (137%;
p 0.001), corpus callosum (151%; p 0.001), cerebellar white
matter (140%; p  0.037), and spinal cord white (124%; p 
0.035) and gray matter (134%; p 0.009) (Fig. 3D).
We performed similar morphological and quantitative analy-
ses of Iba1 cells at the day 5 time point and observed an overall
35 10.6% increase in Iba1 cells specifically in DT-challenged
MBP-DTR mice relative to controls; however, this increase was
not statistically significant (multivariate ANOVA, p 0.737).We
also assessed the relationship between Iba1 microglia and oli-
godendrocytes at this early time point by colabeling for Iba1 and
CC-1 (Fig. 3E–G). Microglia were frequently in close association
with CC-1 somata. Occasional local aggregations of microglia
in contact with CC-1 oligodendrocyte cell bodies were identi-
fied in oligodendrocyte-dense areas such as the corpus callosum
and cerebellar white matter (Fig. 3G, arrowheads).
We next assessed for evidence of reactive astrogliosis following
oligodendrocyte ablation by qualitative analysis of GFAP immuno-
reactivity in sections of the brain and spinal cord in DT-challenged
MBP-DTRmice at clinical end point and in matched controls.
Increased cellular GFAP immunoreactivity was evident in nu-
merous regions, including the neocortex, striatum, and spinal
cord (Fig. 3H–J ); although in some regions, most notably the
corpus callosum, no such response was identified.
Absence of CD3 T-cell infiltration into the CNS following
oligodendrocyte ablation
We next sought to assess whether the oligodendrocyte-initiated
injury in the MBP-DTR model was associated with the recruit-
ment of peripheral T-cells into the CNS.We examined the brains
and spinal cords of DT-challenged MBP-DTR (n  10), saline-
injected MBP-DTR (n  6), and DT-challenged wild-type con-
trols (n  9) by immunohistochemical analysis for the T-cell
antigen CD3. Animals were assessed both at 5 d following injec-
tion and at the clinical end point. CD3 cells were rarely ob-
served in any tissue samples examined. At both time points only
one CD3 T-cell was identified for every two or three tissue
Figure 3. Increased microglial density and GFAP immunoreactivity following oligodendrocyte apoptosis. A–C, Immunohistochemistry against the microglial/macrophage marker Iba1 in the
ventrolateral aspect of the spinal cord ofMBP-DTR saline (A), wild-type DT (B), andMBP-DTR DT (C) mice.MBP-DTR DTmice were collected at clinical end point andmatching controls
were examined at the same time point following saline or DT injection. Nuclei were identified with Hoechst (blue). Note the increased intensity of Iba1 staining in the section from a DT-challenged
MBP-DTRmouse (C).D, Density of Iba1 cells in gray andwhitematter regions of the brain and spinal cord were increased in DT-challengedMBP-DTRmice at clinical end point. E–G, Multicellular
aggregates of Iba1 cells (E, red) amongCC-1oligodendrocytes (F, green) assessed 5d after DT challenge inMBP-DTRmice. Note the close cell– cell contact between Iba1microglia andCC-1
oligodendrocytes (G, arrowheads).H–J, Assessment of GFAP immunoreactivity (green) in the ventrolateral aspect of the spinal cord ofMBP-DTR saline (H), wild-typeDT (I), andMBP-DTR
DT (J) mice reveals evidence of reactive astrogliosis inMBP-DTR DTmice (J) at clinical end point. Scale bars: (in C, J) A–C,H–J, 100m; (in G) E–G, 25m. Cb, cerebellum; CC, corpus callosum;
Ctx, cerebral cortex; GM, gray matter; Str, striatum; SpG, spinal cord gray matter; SpW, spinal cord gray matter; WM, white matter.
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sections assessed, thus providing no evidence for T-cell recruit-
ment into the CNS in this model.
Maintenance of myelin and neuronal preservation following
oligodendrocyte ablation
Demyelination with neuronal preservation can occur as a result
of oligodendrocyte death or dysfunction (Blakemore, 1973;
Traka et al., 2010). To investigate demyelination in the MBP-
DTR model, sections from DT-challengedMBP-DTRmice (n
7) and wild-type counterparts (n  6), as well as saline-injected
MBP-DTRmice (n 3), were analyzed immunohistochemically
for expression of the myelin proteins, 2,3-cyclic nucleotide 3-
phosphodiesterase (CNPase; Fig. 4A–C) and MAG (Fig. 4E–G)
at clinical end point. CNPase andMAG proteins were chosen for
analysis as they are both lost early during experimental demyeli-
nation (Felts et al., 2005) and in pattern III lesions in MS (Luc-
chinetti et al., 2000; Aboul-Enein et al., 2003; Marik et al., 2007),
and are therefore considered robust immunohistochemical
markers of demyelination. Quantitative analysis of the fluores-
cence intensity in photomicrographs using ImageJ revealed no
changes in RIP (CNPase) orMAG labeling in any of the analyzed
regions of the DT-challenged MBP-DTR transgenic mice when
comparedwith controls (Fig. 4D,H; two-wayANOVA, p 0.728
and p  0.602, respectively). Immunohistochemical analysis
therefore failed to provide any evidence of overt demyelination in
symptomatic mice.
To further investigate the integrity of the myelin sheath, we
examined axial sections of the dorsal funiculus of the lumbar
spinal cord using electronmicroscopic analysis. The dorsal funic-
ulus was selected for ultrastructural analysis since it contains ax-
ons integrally involved in the control of motor function and
CC-1 cell counts revealed a 39.5 5.2% reduction in oligoden-
Figure 4. Maintenance of normal levels of CNSmyelin and neuronal preservation at clinical end point in symptomaticmice.A–C, Immunohistochemistry against themyelinmarker RIP (CNPase)
on coronal forebrain sections ofMBP-DTR saline (A), wild-type DT (B), andMBP-DTR DT (C) mice revealed no distinguishable change in RIP immunoreactivity in the primary motor cortex
(M1) among the 3 experimental groups. D, Quantitative analysis of photomicrographs of RIP-labeled CNS tissue revealed no significant change in mean fluorescent pixel density in gray and white
matter regions of the brain and spinal cord. E–G, Immunohistochemistry against the myelin marker MAG in spinal cord sections fromMBP-DTR saline (E), wild-type DT (F), andMBP-DTR
DT (G) mice revealed no obvious change in immunoreactivity among the 3 experimental groups. H, Quantitative analysis of photomicrographs of MAG-labeled CNS tissue revealed no significant
change inmean fluorescent pixel density in gray andwhitematter regions of the brain and spinal cord. I, J, Electronmicrographs of ultrathin transverse sections of the dorsal funiculus of the lumbar
spinal cord of wild-typeDT (I) andMBP-DTR DT (J) mice at clinical end point revealed normal-appearing myelinated axons. K, Comparison of g-ratios for axons in the dorsal funiculus of the
spinal cord revealed a 2.1% reduction inmeang-ratio for axons of DT-challengedMBP-DTRmice versusDT-challengedwild-type controls. L, Scatterplot of g-ratio against axonal diameter of neurons
in the dorsal funiculus. Linear regression analysis revealed that the slope of the line of best fit was significantly lower for DT-challengedMBP-DTRmice comparedwithwild-typemice ( p 0.0057).
This analysis indicates that the g-ratios of larger caliber axons are reduced in DT-challengedMBP-DTRmice relative to controls.M, Evidence of a left shift in the frequency distribution of axons with
a given g-ratio divided into 0.025 bins suggestsmoderate swelling of oligodendrocytemembranes at themyelin internode.N, Frequency distribution of axon diameters (divided into 0.05mbins)
was similar for DT-challengedMBP-DTRmice and controls indicating no differences in the proportion of axons of a given diameter. O, Immunohistochemical analysis of the spinal cord revealed no
difference in the number of neuronal cell bodies (NeuN) per millimeter squared in DT-challengedMBP-DTR versus wild-type mice. Immunohistochemical analysis of the spinal cord revealed no
difference in the number of axons (SMI312) per millimeter squared in DT-challengedMBP-DTR versus wild-typemice. Nd, not determined. Scale bars: (in A, G) A–C, E–G, 200m; (in J) I, J, 200
m. AC, anterior commissure; CbW, cerebellar white matter; CC, corpus callosum; Ctx, cerebral cortex; SpW, spinal cord gray matter.
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drocyte cell bodies in this region (see
above). Sections were prepared from both
MBP-DTR (n 2) and wild-type (n 2)
mice challenged withDT and examined at
the clinical end point for the MBP-DTR
mice (Fig. 4 I, J). Measurements of fiber
and axon areas were used to calculate
g-ratios (Fig. 4K–M). Themean g-ratio of
axons from DT-challenged MBP-DTR
mice was 2.1% less than that of DT-
challenged wild-type controls (Fig. 4K;
p  0.0103, Mann–Whitney test). Plot-
ting g-ratios against axonal diameters re-
vealed that g-ratios of larger caliber axons
were reduced in DT-challenged MBP-
DTR mice relative to controls (Fig. 4L;
slope of line of best fit:MBP-DTR DT,
0.035  0.014; wild-type  DT, 0.087 
0.013; p 0.0057). Consistent with these
data, frequency distributions of g-ratios
revealed a left shift in the population
suggestive of moderate swelling of oli-
godendrocyte membranes at the myelin
internode (Fig. 4M). This conclusion was
supported by the finding that mean axon
diameter was not different in the two
groups (MBP-DTR  DT, 0.72  0.02;
wild-type  DT, 0.68  0.02; p  0.223,
Mann–Whitney test) and the distribution
of axonal diameters remained unaltered
(Fig. 4N). Collectively, these findings in-
dicate that in regions of oligodendrocyte
cell body loss in symptomatic MBP-DTR
mice challenged with DT there is no overt
demyelination and that compact myelin
remains essentially intact (Fig. 4 I, J).
To investigate neuronal loss in the
MBP-DTR model, spinal cord sections
from DT-challenged MBP-DTR mice
(n  7) and wild-type counterparts (n 
6) were analyzed immunohistochemically
for expression of neuronal markers (Fig.
4O,P). This revealed no difference in the
number of neuronal cell bodies (NeuN,
p  0.4714) or the number of axons
(SMI312, p  0.7753) per millimeter
squared inDT-challengedMBP-DTR ver-
sus wild-type mice. Similarly, assessment
Figure 5. Pathological changes in axons and nodes of Ranvier following oligodendrocyte ablation. A–F, Immunohistochemis-
try againstAPP (A,D, red) andRIP (B,E, green) in the cerebral cortex (A–C) and corpus callosum(D–F) of aDT-challengedMBP-DTR
mouse. Note the APP spheroid (A, arrow) proximal to an RIP-labeled myelinated fiber (B, arrowheads) shows evidence of APP
accumulation along its length. C and F show the merged images with Hoechst 33342 counterstain. G, H, Immunohistochemical
assessment of Nav1.6 (red) and Kv1.2 (green) expression at nodes of Ranvier in longitudinal sections of the dorsal funiculus of the
lumbar spinal cord revealed lengthening of the Nav1.6-expressing domain at the node in symptomatic DT-challengedMBP-DTR
mice (H) comparedwith the DT-challengedwild-typemice (G). Note the difference in linearmeasures of Nav1.6 labeling for given
nodes inH versus G. I, J, Immunohistochemical labeling of neurofascin (Nfasc, green) and ankyrin G (red) in longitudinal sections
of the dorsal funiculus of the lumbar spinal cord revealed lengthening of the ankyrin G-labeled domain at the node of DT-
challengedMBP-DTRmice (J, indicated bywhite bars) and reduced or abnormally distributedNfasc expression.K, Quantification of
the density of nodal Nav1.6 expression revealed no change in node density within dorsal, lateral, or ventral aspects of the lumbar
spinal cord. L, Measurement of the length of ankyrin G expression at nodes demonstrated a significant overall effect of genotype
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(p  0.0001, two-way ANOVA) and post hoc analysis con-
firmed genotype-specific differences in the dorsal funiculus
(p 0.0001) and lateral column (p 0.01, Bonferroni’s post
hoc analysis).M, Frequency plot of node length demonstrated
a right shift in the distribution of node lengths inMBP-DTR
DTmice as opposed to wild-type DTmice.N, Percentage of
nodes defined by discrete ankyrin G expression that exhibited
bilateral neurofascin (Nfasc) labeling. Two-way ANOVA re-
vealed a significant overall effect of genotype ( p 0.0001)
and a significant effect of genotype in both dorsal ( p 0.01)
and lateral ( p 0.05) spinal cord (Bonferroni’s post hoc anal-
ysis). Dors., dorsal; Lat., lateral; Vent., ventral. Data represent
mean SEM. Scale bars: (in C)A–E, 25m; (in J)G–J, 5m.
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of axonal density in coronal sections of the
hindbrain of DT-challenged MBP-DTR
andwild-typemice, a region that exhibiteda
23.3% reduction in CC-1 cell bodies, did
not reveal any difference in the density of
SMI312 axons (data not shown). Collec-
tively thesedata indicate that functional def-
icits at the clinical end point are not due to
neuronal or axonal loss.
Axonal injury is observed following
oligodendrocyte ablation
The severe clinical phenotype observed in
DT-challenged MBP-DTR mice suggests
that a significant neuropathology induced
by oligodendrocyte cell death could occur
even though gross structural integrity and
myelination were preserved. To investi-
gate this issue further, we looked for evi-
dence of an underlying axonal pathology
in symptomatic DT-challenged MBP-
DTR mice. First, we assessed sections for
the accumulation of axonal spheroids
containing amyloid precursor protein
(APP), a robust indicator of acute damage
to axonal structure (Trapp et al., 1998).
Throughout the CNS of symptomatic
DT-challenged transgenic mice, but not
controls, APP axonal spheroids of3 to 5m in diameter were
visible but at very low density (Fig. 5A,D; approximately two to
three per coronal section).When sectionswere colabeledwith the
myelin marker RIP and visualized under high magnification,
APP spheroids were found in regions that remained heavily
myelinated (Fig. 5B,E). Accumulation of APP along the length of
myelinated (RIP) axons was also observed (Fig. 5C), indicating
that the infrequent observation of axonal pathology was not re-
stricted to rare demyelinated fibers.
Axonal node length is increased and paranodal neurofascin
labeling is reduced in the spinal cord of symptomaticMBP-
DTRmice
Wenext assessed evidence for changes in the expression profile of
proteins normally clustered at the node of Ranvier and paranode
that are required for fast axonal conduction (Vabnick and
Shrager, 1998). Longitudinal sections of the spinal cord of DT-
challengedMBP-DTRmice (n 5) andDT-challengedwild-type
littermates (n  4) were collected at the clinical end point and
immunolabeled for Nav1.6 and Kv1.2 (Fig. 5G,H), proteins nor-
mally localized to the node and juxtaparanode, respectively (Po-
liak and Peles, 2003). In animals treated with DT, we observed an
increase in the average length of the Nav1.6 expression domain at
the node, suggesting dispersal of sodium channels following DT
administration (Fig. 5G,H, linear measurements). In contrast,
Kv1.2 labeling appeared normal in symptomatic animals.
Given the dispersed pattern of Nav1.6 expression at the node,
we next examined the expression of ankyrin G, a structural pro-
tein that plays a critical role in clustering voltage-gated sodium
channels at the node. To identify nodes, ankyrin G-stained sec-
tions were colabeled with a pan-neurofascin (Nfasc) antibody
that detects both oligodendrocyte-specific (Nfasc155) and
neuron-specific (Nfasc186) isoforms (Tait et al., 2000) (Fig.
5 I, J). First, we quantified node density on the basis of Nav1.6
labeling and observed no significant differences between DT-
challengedMBP-DTRmice and controls in the dorsal, lateral, or
ventral column of the lumbar spinal cord (Fig. 5K; overall effect
of genotype, p  0.5202; 2-way ANOVA), consistent with the
normal density of SMI312 axons previously described. Mea-
surement of the length of the ankyrin G-expressing domain at
nodes revealed an increase in node length in symptomatic DT-
challengedMBP-DTR animals relative to controls (Fig. 5L; over-
all effect of genotype, p 0.0001; 2-way ANOVA). Bonferroni’s
post hoc analysis revealed that relative to controls, node length in
DT-challengedMBP-DTRmice was significantly increased in the
dorsal funiculus (p 0.0001) and lateral column (p 0.01) but
not in the ventral column (p	 0.05). To analyze node lengthen-
ing in greater detail, the lengths of ankyrin G-labeled nodes in
dorsal, lateral, and ventral columns were grouped into 0.4 m
bins and plotted to generate a frequency distribution of overall
node lengths in the lumbar spinal cord of DT-challenged MBP-
DTR animals compared with wild-type controls (Fig. 5M). The
plot reveals a right-shifted distribution of node lengths for DT-
challengedMBP-DTR animals relative to controls. Analysis of the
curve of best fit (data not shown) revealed that the two frequency
distributions were significantly different (extra sum-of-squares F
test, p 0.0001).
We also noted changes in the profile of neurofascin expression
in regions outside the ankyrin G-expressing domain, considered
to represent the oligodendrocyte-specificNfasc155 isoformat the
paranode. Many nodes in DT-challenged MBP-DTR mice dem-
onstrated almost complete loss of Nfasc155 labeling. This was of
particular interest given the integral role of Nfasc155 in establish-
ing axoglial structure at the paranode (Zonta et al., 2008). In
contrast, the expression profile of neurofascin within the ankyrin
G-expressing domain, likely reflecting the expression of neuron-
specific Nfasc186, was preserved. Overall, compared with DT-
challenged wild-type controls, symptomatic DT-challenged
MBP-DTRmice exhibited a 12 1.2% reduction in the percent-
age of nodes atwhichNfasc155was present (Fig. 5N;overall effect
Figure 6. Dissociation of paranodal loops from the axolemma ofmyelinated neurons in the spinal cord following oligodendro-
cyte ablation. A–D, Electron microscopic assessment of nodes of Ranvier in longitudinal sections of the dorsal funiculus of the
lumbar spinal cord revealed thenature of the interaction of paranodal loops and the axolemmaofDT-challengedwild-type (A) and
DT-challengedMBP-DTRmice (B–D). In all nodes examined in DT-challengedwild-typemice the paranodal loops closely abut the
axon (A, arrowheads). A subset of nodes in DT-challenged MBP-DTR mice also maintained this regular structure (B); however,
many nodes in these animals demonstrated alterations in axonal caliber, accumulation of organelles at the node and paranode (C,
D, arrows), and unfurling or frank disconnection of paranodal loops from the axon (C,D, arrowheads). Therewas a 59.4% increase
in the number of nodes described as abnormal (unpaired Student’s t test). N, node; PN, paranode. Scale bar: (in D) A–D, 1m.
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of genotype: p 0.0001, 2-way ANOVA; specific effects of geno-
type: dorsal, p  0.01; lateral, p  0.05, Bonferroni’s post hoc
analysis).
Abnormalities of myelination in disabledMBP-DTRmice are
restricted to the paranodal region
To clarify the nature of axonal pathology occurring at the node
given the evidence of abnormal protein localization of Nav1.6,
ankyrin G, and neurofascin, we assessed nodes of Ranvier at the
ultrastructural level. We prepared ultrathin sections from the
dorsal spinal cord of two DT-challenged MBP-DTR mice, two
DT-challenged wild-type littermates, and one vehicle-treated
control. In control DT-challenged wild-type mice and a vehicle-
treated transgenic mouse, normal nodal structure was main-
tained (Fig. 6A; wild-type  DT). Paranodal myelin loops were
present abutting the node and tightly juxtaposed to the axonal
membrane, and the axonal caliber was regular. Some nodes from
DT-challenged transgenic mice maintained this regular pattern
(Fig. 6B). However, in a significant proportion of nodes exam-
ined in DT-challenged MBP-DTR mice, substantial abnormalities
were evident with disruption of axonal caliber and accumulation
of organelles at both the node and paranode (Fig. 6C,D). There
was also evidence that themost proximal paranodalmyelin loops
(i.e., those closest to the node) were “disconnected” from the
axon and everted away from the axon, disrupting the regular
structure present at normal nodes (Fig. 6C,D, arrowheads). In
some cases, paranodes were completely dissociated from the axo-
lemma, reminiscent of the loss of oligodendrocyte-specific neu-
rofascin labeling characterized immunohistochemically.We next
extended this assessment to a quantitative analysis of ultrastruc-
tural changes in the nodes of Ranvier in longitudinal sections of
the dorsal funiculus within the lumbar spinal cord of both vehicle
and DT-challenged MBP-DTR mice. We found that 59.4% of
nodes in theDT-challengedMBP-DTRmice exhibited paranodal
loop eversion which was never observed in DT-challenged wild-
type mice (n  32 MBP-DTR  DT, n  14 wild-type  DT
paranodal domains). Collectively, these data indicate that admin-
istration of DT leads to significant changes in structure of the
nodes and paranodes and the distribution of organizational pro-
teins. As a result, there are significant changes in the distribution
of ion channels that determine saltatory conduction velocity in
these axons.
Peripheral nerve myelination and conduction are unaffected
in DT-challengedMBP-DTRmice
Given that the endogenous MBP gene is expressed not only in
oligodendrocytes but also in myelinating Schwann cells (Lemke,
1988) we also assessed the consequences of DT challenge in the
peripheral nervous system (PNS) of theMBP-DTRmice. Immu-
nohistochemical staining of the sciatic nerve revealed that there
was low-level expression of DTR proximal to the node of Ranvier
(Fig. 7A,B). Double labeling confirmed that DTR was localized
within perinodal microvilli of Schwann cells defined by expres-
sion of ezrin (Fig. 7C–E), surrounding the domain of axonal
Nav1.6 expression (Fig. 7F–H). To assess whether Schwann cells
were ablated followingDT challenge, we quantified the density of
Krox20 cells in the sciatic nerve and found a 33.1  7.3% re-
duction in the number of Krox20 Schwann cells at clinical end
point (585  54/mm2 in wild-type  DT mice versus 391 
43/mm2 MBP-DTR  DT mice, n  3 per group; p  0.048,
unpaired Student’s two-tailed t test). Ultrastructural analysis of
the sciatic nerves revealed that myelination is normal in the DT-
challengedMBP-DTRmice compared with DT-challenged wild-
type (Fig. 7 I, J), consistent with our observations concerning
myelination in the CNS. Plotting g-ratio against axon diameter
revealed similar distributions for both experimental groups (Fig.
7K) with a mean g-ratio of 0.6085 0.0036 inMBP-DTRDT
mice compared with a mean g-ratio of 0.6031  0.003 in wild-
typeDTmice (p 0.258, unpaired Student’s two-tailed t test).
To assess peripheral nerve function in thesemicewemeasured
compound action potential conduction in isolated sciatic nerves
from DT-challenged MBP-DTR and wild-type mice (n  8 and
three nerves per group, respectively). In contrast to the signifi-
cant reduction in the velocity and amplitude of central conduc-
tion measured by SSEP assessment, no significant alteration in
peripheral nerve CAPs was observed in nerves isolated from the
DT-challenged MBP-DTR mice (Fig. 7L; latency of CAP re-
sponse: 1.247 0.009 ms inMBP-DTRDT (n 8) compared
Figure 7. Preservation of peripheralmyelination and conduction in the sciatic nerve ofMBP-DTRmice.A,B, Immunohistochemical analysis of DTR expression in the sciatic nerve of unchallenged
MBP-DTR (A) andwild-type control (B) mice revealed restricted foci of DTR protein within the perinodal regions ofMBP-DTR nerves (B, arrowheads). C–E, Colocalization of perinodal DTR (C, green)
with the Schwann cell microvillar marker ezrin (D, red). F–H, Microvillar DTR expression (F, green) in the sciatic nerve surrounds domains of axonal Nav1.6 expression (G, red). I, J, Electron
micrographs of transverse sections of the sciatic nerve of wild-typeDT (I) andMBP-DTR DT (J) mice at clinical end point revealed normal-appearingmyelinated axons. K, Scatterplot of g-ratio
against axondiameter revealednodifferences betweenDT-challengedMBP-DTRmice (red) andDT-challengedwild-type controls (blue). L, Electrophysiological assessment of acutely isolated sciatic
nerves revealed no significant alteration in peripheral nerve CAPs in DT-challengedMBP-DTRmice versus wild-type mice. Scale bar, (in A, E, H, I) A–J, 10m.
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with 1.225  0.014 ms in wild-type  DT mice (n  3); p 
0.231, Student’s two-tailed t test). Collectively these data suggest
that Schwann cells are targeted by DT challenge but that both
myelination and peripheral nerve electrophysiological parame-
ters are unaltered. We therefore conclude that Schwann cell tar-
geting in the PNS is likely to be, at most, a minor contributor to
the overall phenotype of the DT-challenged mice.
Discussion
Here we describe the generation and characterization of a novel
model of conditional oligodendrocyte ablation using transgenic
mice that express DTR in oligodendrocytes throughout the CNS.
In response to systemic DT administration,MBP-DTRmice pro-
gressively developed profound clinical disability characterized by
ataxia, spastic paralysis of the hindlimbs, kyphosis, weight loss,
and ultimately respiratory paralysis within 22 d of DT injection.
At clinical end point, mice exhibited the loss of 26% of oligo-
dendrocyte cell bodies throughout the CNS but maintained nor-
mal g-ratios and normal levels of MAG and CNP proteins
indicating no overt demyelination. Schwann cells were also tar-
geted; however, their loss was not associated with abnormalities
of peripheral nerve conduction and the animals displayed a spas-
tic rather than a flaccid paralysis, indicative of a central rather
than a peripheral clinical deficit. Disabled mice displayed ever-
sion of paranodal loops away from the axolemma and altered
distribution of ion channels and structural proteins at both the
nodes of Ranvier and paranodes resulting in nodal lengthening.
Although axonal density within the spinal cord was unaltered,
axonal pathology was evident from APP accumulation within
axonal swellings and an increased SSEP latency indicative of re-
duced conduction velocity. Collectively, these data reveal a criti-
cal role for oligodendrocytes in maintaining the structural and
functional integrity of axons that is distinct from the provision of
myelin.
Comparison with other models of conditional
oligodendrocyte ablation
Previously described binary genetic models of conditional oligo-
dendrocyte ablation were established by crossing two transgenic
lines to direct Cre-mediated expression of DT-A or DTR in ma-
ture oligodendrocytes (Buch et al., 2005; Traka et al., 2010; Pohl
et al., 2011). Despite the different genetic strategies used to in-
duce oligodendrocyte ablation, all transgenic models exhibit a
similar clinical phenotype but differ with respect to time of symp-
tom onset and clinical course, with MBP-DTR mice exhibiting
the most rapid and severe phenotype. Whereas the former mod-
els are associated with overt CNS demyelination and/or myelin
vacuolation, DT-challengedMBP-DTRmice exhibited profound
clinical disability and axonal pathology before these histopatho-
logical features appear. Myelin preservation in symptomatic DT-
challengedMBP-DTRmice at clinical end point (16 d post-DT
administration) suggests that degenerative mechanisms respon-
sible for degradation of compact myelin following oligodendro-
cyte apoptosis are not fully induced before the clinical end point.
Comparatively, demyelination inMOGi-Cre:iDTR (oDTR) mice
(Buch et al., 2005; Locatelli et al., 2012) and PLP/CreERT:
ROSA26-eGFP-DTAmice (Traka et al., 2010) was first observed
28 and 35 d postchallenge, respectively, whereas reduced MBP
immunoreactivity in PLP-CreERT2:R26-LacZ/DT-A mice was
prominent at 39–42 d post tamoxifen (Pohl et al., 2011). The
rapid onset of clinical pathology inMBP-DTRmice within 9–12
d after a single DT injection likely reflects the high-level consti-
tutive expression of DTR by oligodendrocytes that renders the
population highly sensitive to DT-mediated cytotoxicity. In con-
trast, the binary genetic models rely upon repetitive administra-
tion of tamoxifen (Traka et al., 2010; Pohl et al., 2011) or DT
(Buch et al., 2005; Locatelli et al., 2012) over several days that
would be expected to induce an asynchronous course of DT-
mediated cytotoxicity and cell death rather that the acute toxicity
observed in the MBP-DTR model. In addition to differences in
kinetics, the percentage depletion of oligodendrocytes across var-
ious regions of gray and white matter will reflect the specific Cre
drivers and floxed alleles that are used and the precise regimen of
tamoxifen or DT that is administered (Saito et al., 2001; Leone et
al., 2003).
Conduction impairment is associated with disruption of
nodes and paranodes
The clinical presentation of ataxia and hindlimb paralysis was
corroborated by increased latency of SSEP recordings. Structur-
ally, we observed the presence of axonal spheroids at low density
throughout theCNSofDT-challengedMBP-DTRmice, amarker
of early axonal pathology and transection (Trapp et al., 1998).
Ultrastructural analysis revealed disorganization of paranodal
structure within spinal cord white matter characterized by ever-
sion of the paranodal loops from the axolemma. Since node and
fiber density were unaltered in symptomatic mice, the observa-
tion that only a subset of nodes exhibited increased nodal Nav1.6
and ankyrin G expression suggests that paranodal eversion likely
precedes redistribution of Nav1.6 and ankyrin G. Current under-
standing of paranodal structure and function support this con-
clusion. Tight axoglial junctions at the paranode form via high
molecular weight complexes between the axonal proteins caspr
and contactin and oligodendrocyte Nfasc155 (Tait et al., 2000;
Bhat et al., 2001). By preventing lateral membrane diffusion, the
paranode maintains voltage-gated Na and K channels at high
concentration at the node and juxtaparanode, respectively,
thereby enabling fast saltatory conduction (Sherman and
Brophy, 2005). In symptomaticMBP-DTRmice, maintenance of
Kv1.2 expression within the juxtaparanode but dispersal of nodal
Nav1.6 therefore likely reflects the selective disruption of paran-
odal loops located closest to the node but preservation of distal
loop attachment to the axolemma.
The nodal and paranodal changes observed in MBP-DTR
mice bear similarities to defects in a number of myelin and para-
nodal protein-mutant mice and with changes observed in MS
tissue. Notably, mice deficient in Nfasc155 or Caspr do not form
normal paranodes and exhibit aberrant clustering of voltage-
gated ion channels on axons resulting in various motor deficits
(Bhat et al., 2001; Rios et al., 2003; Pillai et al., 2009). In MS
subjects, Caspr and Nfasc155 are abnormally distributed on
myelinated axons that border chronic demyelinated lesions
(Wolswijk and Balesar, 2003; Howell et al., 2006) suggesting that
changes in paranodal integrity could occur at the leading edge of
MS lesion formation before demyelination. Paranodal eversion
has also been described in transgenic mice with additional copies
of the plp gene (Tanaka et al., 2009) and inCGTmutantmice that
have aberrant but viable oligodendrocytes (Dupree et al., 1998).
Dispersal of nodal proteins away from the node and paranodal
disruption characterized by loss of the axoglial junctions there-
fore appear to be a common mechanism leading to functional
deficits that can occur in isolation or coincident with demyelina-
tion. Independent of the initiating event, these pathological
changes at the node and paranode are likely to contribute to
failure of saltatory conduction and reduced conduction velocity.
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Immune activity and myelination
The activation, proliferation, recruitment, and conversion of mi-
croglia to a phagocytic amoeboid phenotype is an important cel-
lular response that contributes to clearance of myelin debris in
various models of CNS demyelination (Merson et al., 2010). In
contrast, DT-challenged MBP-DTR mice exhibited only a mod-
est increase in microglial cell density that retained a ramified
morphology with evidence of process thickening reminiscent of
“prephagocytic” lesions in early MS cases (Barnett and Prineas,
2004), and “predemyelinating” lesions described by Marik et al.
(2007). Nevertheless, close apposition betweenmicroglia and oli-
godendrocyte cell bodies 5 d following DT administration sug-
gests that microglia are responsive to early alterations in
oligodendrocyte physiology. Importantly, microglia are capable
of phagocytosing damaged cells andmembranes without exhibiting
an amoeboid morphology (Davalos et al., 2005; Nimmerjahn et al.,
2005; Kim and Dustin, 2006) and rapid clearance of apoptotic cell
bodies does not stimulate a proinflammatory response in macro-
phages (Gregory and Devitt, 2004; Town et al., 2005). Thus micro-
glia in MBP-DTR mice could participate in restricted “surgical”
phagocytosis of the cell bodies of apoptotic oligodendrocytes with-
out conversion to an amoeboid phenotype required for efficient
phagocytosis of compact myelin debris.
It was also notable that there was no adaptive immune re-
sponse consistent with previous observations in oligodendrocyte
ablation models (Buch et al., 2005; Traka et al., 2010; Pohl et al.,
2011; Locatelli et al., 2012). The absence of lymphocyte infiltra-
tion has also been observed in acute MS lesions (Barnett and
Prineas, 2004; Henderson et al., 2009) and therefore does not
mitigate against the potential relevance of this model to MS. The
essential issue that remains in testing the veracity of Barnett and
Prineas’ (2004) hypothesis of oligodendrocytopathy as a poten-
tial cause of MS is to determine whether there are downstream
circumstances in which the adaptive immune system does be-
come activated, as occurs in chronic MS. The recent study by
Locatelli et al. (2012), demonstrating that oligodendrocyte cell
death failed to potentiate anti-CNS immunity, even in the con-
text of potent induction of T-cell activation and inflammation,
suggests that autoimmunity is not readily modulated by oligo-
dendrocyte death. Thus an important issue in addressing Barnett
and Prineas’ (2004) hypothesis will be to establish how engage-
ment with the immune system differs between models of oligo-
dendrocytopathy that induce T-cell recruitment into the CNS (Ip
et al., 2006; Kassmann et al., 2007) and models of oligodendro-
cyte cell death that do not.
Concluding remarks
We have demonstrated that oligodendrocyte cell death disrupts
the normal structural and molecular integrity of paranodes and
nodes of Ranvier, leading to impaired conduction of action po-
tentials and a gross clinical phenotype despite maintenance of
normal myelin internodes. The direct expression of DTR in ma-
ture oligodendrocytes has many attractive features as a model for
oligodendrocyte ablation. Unlike existing binary genetic ap-
proaches to ablate oligodendrocytes, the MBP-DTR model pro-
vides unlimited freedom to apply Cre/loxP genetics to further
explore pathogenic mechanisms. Moreover, this phenotype is
elicited with a single dose of DT, enabling clear dissociation of
reactive changes that could otherwise occur contemporaneously
in the binary genetic models. TheMBP-DTRmodel will facilitate
the analysis of the early events involved in the breakdown of the
symbiotic relationship between oligodendrocytes and axons. Our
results clearly demonstrate that axonal impairment occurs be-
fore, or in the absence of, demyelination. This phenotype closely
mirrors the early MS lesion, i.e., the prephagocytic lesions de-
scribed by Barnett and Prineas (2004), as well as the predemyeli-
nating lesions described byMarik et al. (2007) and Pattern IIIMS
lesions (Lucchinetti et al., 2000), providing an opportunity to
elucidate the processes that lead to demyelination and axonal
degeneration and the relationship between the events. Impor-
tantly, the data also serve to illustrate that the genesis of axonal
pathology in the absence of demyelination in recent onset disease
could be induced by an oligodendrocytopathy.
Oligodendrocytes have been proposed to play an integral role
in the maintenance of axonal function by providing trophic sup-
port to axons via the provision of energy-rich metabolites to
myelinated axons (Nave, 2010). Further evaluation of the MBP-
DTRmodel will help clarify the molecular mechanisms that govern
oligodendrocyte–axon interactions, and the types of metabolites
that might be supplied to axons. Ascertaining the nature of the
cytokine profile that predominates in the MBP-DTRmodel, and
contrasting it with that which prevails in demyelinating models
could delineate the molecular mechanisms regulating axonal de-
generation on the one hand and myelin breakdown and
microglial-mediated phagocytosis on the other. Such informa-
tion could facilitate our understanding of how these various pro-
cesses are controlled and the circumstances in which it is
appropriate to modulate each of them.
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